| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-04-28 17:15:22 UTC |
|---|
| Updated at | 2022-04-28 17:15:22 UTC |
|---|
| NP-MRD ID | NP0071878 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | (2S,3R,4E)-2-N-Palmitoyloctadecasphinga-4-ene |
|---|
| Description | Cer(d18:1/16:0), Also known as C16 cer or ceramide, belongs to the class of organic compounds known as long-chain ceramides. These are ceramides bearing a long chain fatty acid. Thus, cer(D18:1/16:0) Is considered to be a ceramide lipid molecule. (2S,3R,4E)-2-N-Palmitoyloctadecasphinga-4-ene is found in Junceella juncea and Trypanosoma brucei. (2S,3R,4E)-2-N-Palmitoyloctadecasphinga-4-ene was first documented in 1994 (PMID: 8163674). Cer(d18:1/16:0) Is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral (PMID: 14722105) (PMID: 9545298) (PMID: 15067322) (PMID: 14693694). |
|---|
| Structure | [H][C@@](CO)(NC(=O)CCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC InChI=1S/C34H67NO3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33(37)32(31-36)35-34(38)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h27,29,32-33,36-37H,3-26,28,30-31H2,1-2H3,(H,35,38)/b29-27+/t32-,33+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (2S,3R,4E)-2-Acylamino-1,3-octadec-4-enediol | ChEBI | | (2S,3R,4E)-2-Acylaminooctadec-4-ene-1,3-diol | ChEBI | | C16 Cer | ChEBI | | C16 Ceramide | ChEBI | | C16-0(Palmitoyl)ceramide | ChEBI | | Ceramide (D18:1/16:0) | ChEBI | | N-(Hexadecanoyl)-sphing-4-enine | ChEBI | | N-(Hexadecanoyl)ceramide | ChEBI | | N-(Hexadecanoyl)sphing-4-enine | ChEBI | | N-(Palmitoyl)ceramide | ChEBI | | N-Hexadecanoyl-D-erythro-sphingosine | ChEBI | | N-Hexadecanoylsphing-4-enine | ChEBI | | N-Palmitoyl-sphingosine | ChEBI | | N-Palmitoylsphing-4-enine | ChEBI | | N-Palmitoylsphingosine | ChEBI | | Cer | HMDB | | Ceramide | HMDB | | N-Acylsphingosine | HMDB | | N-[(1S,2R,3E)-2-Hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-octadecanamide | HMDB | | C16-Ceramide | HMDB | | NFA(C16)cer | HMDB | | Palmitoylceramide | HMDB | | C(16)-Ceramide | HMDB | | N-Palmitoylsphingosine, (r*,s*-(e))-(+-) | HMDB | | C16-Palmitoylceramide | HMDB | | N-Palmitoylsphingosine, R-(r*,s*-(e)) | HMDB | | PCer CPD | HMDB | | Ceramide-C16 | HMDB | | (2S,3R,4E)-2-N-Palmitoyloctadecasphinga-4-ene | HMDB | | C16:0-Ceramide | HMDB | | Ceramide (D18:1,C16:0) | HMDB | | Ceramide 16 | HMDB | | Ceramide(D18:1/16:0) | HMDB | | D-Erythro-C16-ceramide | HMDB | | D-Erythro-N-hexadecanoylsphingenine | HMDB | | D-Erythro-N-palmitoylsphingosine | HMDB | | D-Erythro-delta4-ceramide | HMDB | | D-Erythro-δ4-ceramide | HMDB | | N-Hexadecanoyl-D-erythro-ceramide | HMDB | | N-Hexadecanoylsphingosine | HMDB | | N-Palmitoyl 4-sphingenine | HMDB | | N-Palmitoyl ceramide | HMDB | | N-Palmitoyl-D-erythro-sphingosine | HMDB | | N-Palmitoyl-D-sphingosine | HMDB | | N-(Hexadecanoyl)-sphingosine | MetBuilder | | N-(Hexadecanoyl)-D-erythro-sphingosine | MetBuilder | | N-(Hexadecanoyl)-4-sphingenine | MetBuilder | | N-(Hexadecanoyl)-D-sphingosine | MetBuilder | | N-(Hexadecanoyl)-sphingenine | MetBuilder | | N-(Hexadecanoyl)-erythro-4-sphingenine | MetBuilder | | Cer(D18:1/16:0) | ChEBI |
|
|---|
| Chemical Formula | C34H67NO3 |
|---|
| Average Mass | 537.9007 Da |
|---|
| Monoisotopic Mass | 537.51210 Da |
|---|
| IUPAC Name | N-[(2S,3R,4E)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide |
|---|
| Traditional Name | N-(palmitoyl)-ceramide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@](CO)(NC(=O)CCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC |
|---|
| InChI Identifier | InChI=1S/C34H67NO3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33(37)32(31-36)35-34(38)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h27,29,32-33,36-37H,3-26,28,30-31H2,1-2H3,(H,35,38)/b29-27+/t32-,33+/m0/s1 |
|---|
| InChI Key | YDNKGFDKKRUKPY-TURZORIXSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as long-chain ceramides. These are ceramides bearing a long chain fatty acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Sphingolipids |
|---|
| Sub Class | Ceramides |
|---|
| Direct Parent | Long-chain ceramides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Long-chain ceramide
- Fatty amide
- N-acyl-amine
- Fatty acyl
- Carboxamide group
- Secondary alcohol
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Alcohol
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Deguchi H, Yegneswaran S, Griffin JH: Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem. 2004 Mar 26;279(13):12036-42. Epub 2004 Jan 13. [PubMed:14722105 ]
- Watanabe R, Wu K, Paul P, Marks DL, Kobayashi T, Pittelkow MR, Pagano RE: Up-regulation of glucosylceramide synthase expression and activity during human keratinocyte differentiation. J Biol Chem. 1998 Apr 17;273(16):9651-5. doi: 10.1074/jbc.273.16.9651. [PubMed:9545298 ]
- Mari M, Colell A, Morales A, Paneda C, Varela-Nieto I, Garcia-Ruiz C, Fernandez-Checa JC: Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis. J Clin Invest. 2004 Mar;113(6):895-904. doi: 10.1172/JCI19852. [PubMed:15067322 ]
- Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes. 2004 Jan;53(1):25-31. doi: 10.2337/diabetes.53.1.25. [PubMed:14693694 ]
- Holleran WM, Ginns EI, Menon GK, Grundmann JU, Fartasch M, McKinney CE, Elias PM, Sidransky E: Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest. 1994 Apr;93(4):1756-64. doi: 10.1172/JCI117160. [PubMed:8163674 ]
|
|---|